Relmada Therapeutics (RLMD) Equity Average (2013 - 2026)

Relmada Therapeutics (RLMD) has 14 years of Equity Average data on file, last reported at $152.6 million in Q1 2026.

• Equity Average for Q1 2026 came in at $152.6 million, up 426.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $152.6 million (up 426.62% YoY), and the FY2025 annual result was $61.0 million, up 0.96% from the prior year.
• Equity Average climbed to $152.6 million in Q1 2026 per RLMD's latest filing, from $48.0 million in the prior quarter.
• Over five years, Equity Average peaked at $209.3 million in Q1 2022 and troughed at $12.7 million in Q3 2025.
• A 5-year average of $100.1 million and a median of $93.0 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2025 and 2026: Equity Average tumbled 76.71% in 2025, then surged 426.62% in 2026.
• A 5-year view of Equity Average shows it stood at $153.4 million in 2022, then plunged by 39.34% to $93.0 million in 2023, then plunged by 55.32% to $41.6 million in 2024, then climbed by 15.43% to $48.0 million in 2025, then surged by 218.04% to $152.6 million in 2026.
• Business Quant data shows RLMD's Equity Average at $152.6 million in Q1 2026, $48.0 million in Q4 2025, and $12.7 million in Q3 2025.